Chief Business & Strategy Officer · TCR2 THERAPEUTICS INC. (TCRR)

Rosemary Harrison

FY2022 is the first fiscal year CompBrief holds for Rosemary Harrison as a named executive officer of TCR2 THERAPEUTICS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,066,563

Salary $372,083Stock awards $12,437

2nd of 3 named executive officers at TCR2 Therapeutics by FY2022 total.

3 named officers on file for TCR2 THERAPEUTICS, FY2022

Rosemary Harrison’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how TCR2 THERAPEUTICS’s whole pay program stands against its peers

  • TCR2 THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TCRR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 23, 2023 (10-K).

Free

Get Rosemary Harrison’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Rosemary Harrison compensation by year

TCR2 THERAPEUTICS Summary Compensation Table · the one fiscal year held
In US dollars, as TCR2 THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$372,083
Bonus$0
Stock awards$12,437
Option awards$531,582
Non-equity incentive$140,000
Pension and deferred compensation$0
All other$10,461
Total$1,066,563

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TCR2 THERAPEUTICS INC. 10-K filed March 23, 2023, accession 0000950170-23-009312, and prior-year filings. Open the filing on EDGAR.

How this page was built: the TCR2 THERAPEUTICS INC. filed document, accession 0000950170-23-009312. Every figure is read from that document and cited to the page and table it appears in. Filed March 23, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU46,597$46,597—
TVA—$12,882—
RSU12,882$12,882—
Option76,930—$0.97
Option191,102—$4.04

Per the Outstanding Equity Awards at Fiscal Year-End table in TCR2 THERAPEUTICS INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

TCR2 THERAPEUTICS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Garry MenzelPresident and Chief Executive Officer$1,744,815
Rosemary Harrison · this pageChief Business & Strategy Officer$1,066,563
Alfonso CardamaChief Medical Officer$1,012,109

The full TCR2 THERAPEUTICS compensation record

free company brief

This page is one person within TCR2 THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TCR2 THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Rosemary Harrison's compensation dossier · One-time report. No refunds.